Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2021 · 10-Q
Revenue—
Net Income-$2.71M-$2.71MN/M vs Q3 2020 EPS Diluted-$0.12-$0.12N/M vs Q3 2020 Operating Income-$3,516,869N/M Operating Cash Flowderived-$2,206,203N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end